The combination of hypomethylating agents and histone deacetylase inhibitors (HDACi) are synergistically cytotoxic and reverse the malignant phenotype in preclinical models of T-cell lymphoma.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019175:DNA Methylation / Q000187:drug effects*; D004195:Disease Models, Animal; D004357:Drug Synergism; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000235:genetics; D051379:Mice
D056572:Histone Deacetylase Inhibitors